High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1408-1415

  Pailler, E ^a,b   Auger, N ^b   Lindsay, C R ^a,b   Vielh, P ^a,b   Islas Morris Hernandez, A ^b   Borget, I ^b   Ngo Camus, M ^b   Planchard, D ^b   Soria, J C ^a,b   Besse, B ^b   Farace, Françoise ^a,b  

^a Universite Paris Sud   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Circulating tumor cells; FA FISH; Filtration enrichment; Predictive biomarker; ROS1 rearranged non small cell lung cancer

Indexed keywords

ADULT; AGED; ANEUPLOIDY; ARTICLE; BLOOD LEVEL; CELL LEVEL; CELLULAR DISTRIBUTION; CHROMOSOMAL INSTABILITY; CHROMOSOME REARRANGEMENT; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DNA CONTENT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG BIOPSY; LUNG CARCINOGENESIS; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NON SMALL CELL LUNG CANCER; ONCOGENE; PRIORITY JOURNAL; ROS1 GENE; TUMOR BIOPSY; BLOOD; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; FOLLOW UP; GENE REARRANGEMENT; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS; TUMOR CELL CULTURE; TUMOR EMBOLISM;

CRIZOTINIB; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOMAL INSTABILITY; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; TUMOR CELLS, CULTURED;

EID: 84943654057     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv165     Document Type: Article

References (22)

1. Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010; 9: 363-366.
2. Shames DS, Wistuba II. The evolving genomic classification of lung cancer. J Pathol 2014; 232: 121-133.
3. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
4. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
5. Bergethon K, Shaw AT, Ou SH et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-870.
6. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 2013; 18: 865-875.
7. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 2013; 19: 4040-4045.
8. Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 20: 1963-1971.
9. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
10. Baccelli I, Schneeweiss A, Riethdorf S et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31: 539-544.
11. Hodgkinson CL, Morrow CJ, Li Y et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014; 20: 897-903.
12. Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013; 23: 573-581.
13. Krebs MG, Metcalf RL, Carter L et al. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 2014; 11: 129-144.
14. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
15. Farace F, Massard C, Vimond N et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 2011; 105: 847-853.
16. Krebs MG, Sloane R, Priest L et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011; 29: 1556-1563.
17. Ilie M, Long E, Butori C et al. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol 2012; 23: 2907-2913.
18. Pailler E, Adam J, Barthelemy A et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 2013; 31: 2273-2281.
19. McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep 2012; 13: 528-538.
20. Lee AJ, Endesfelder D, Rowan AJ et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011; 71: 1858-1870.
21. Sato H, Uzawa N, Takahashi K et al. Prognostic utility of chromosomal instability detected by fluorescence in situ hybridization in fine-needle aspirates from oral squamous cell carcinomas. BMC Cancer 2010; 10: 182.
22. Nakamura H, Saji H, Idiris A et al. Chromosomal instability detected by fluorescence in situ hybridization in surgical specimens of non-small cell lung cancer is associated with poor survival. Clin Cancer Res 2003; 9: 2294-2299.